The emotional toll of rare diseases extends far beyond the individual patient, deeply impacting families as they navigate complex diagnoses, limited treatment options, and the often isolating experience of facing the unknown. A recent story from Brazil highlights this struggle, focusing on Andréa Joana da Silva Gomes, a mother of two children diagnosed with the same rare genetic condition: Spinal Muscular Atrophy type 3 (SMA). Her story, shared with Metrópoles, underscores the challenges of delayed diagnosis and the profound impact of rare diseases on families.
Spinal Muscular Atrophy (SMA) is a genetic disease affecting motor neurons, nerve cells in the spinal cord, which control essential muscle functions like breathing, swallowing, and walking. It’s caused by a deficiency in the survival motor neuron (SMN) protein. The Mayo Clinic details that there are different types of SMA, categorized by the age of onset and severity of symptoms. Type 3, the form affecting Andréa’s children, typically manifests in late infancy or early childhood and is characterized by progressive muscle weakness.
A Long Road to Diagnosis
Andréa’s journey to understanding her children’s condition was a protracted one. Her daughter, Noemy, now 13, began exhibiting signs of motor difficulties around the age of one, frequently falling and displaying an atypical gait. Initially, doctors attributed these issues to cerebral palsy, linked to a placental abruption during pregnancy. For nearly nine years, Noemy received physiotherapy based on this initial diagnosis, with some improvement in balance noted, but lingering concerns remained with the therapist who treated her.
The diagnostic odyssey continued until the birth of Andréa’s son, Natan, now 8. As Natan grew, Andréa observed similarities between his development and Noemy’s earlier struggles, prompting her to question the original diagnosis. The realization that both children shared similar symptoms strongly suggested a genetic component. According to Folha de BV, genetic testing is crucial in diagnosing rare diseases in children, with approximately 80% of these conditions having a genetic basis.
genetic testing confirmed that both Noemy and Natan have SMA type 3. This diagnosis brought a sense of clarity, but also a wave of new challenges. The family resides in Rio Pomba, a rural area in Minas Gerais, Brazil, where access to specialized medical care is limited. Andréa has had to seek treatment and consultations in neighboring municipalities, adding to the logistical and financial burdens of managing her children’s condition.
The Global Impact of Rare Diseases
The story of Andréa and her children is not unique. Rare diseases, defined as those affecting a compact percentage of the population – often fewer than 65 people per 100,000, as defined by the World Health Organization (WHO) – collectively affect millions worldwide. More than 300 million people globally live with a rare disease, yet many face significant hurdles in obtaining a diagnosis. According to a report by Estadão, approximately 60% of individuals with rare diseases remain undiagnosed during childhood.
The delay in diagnosis can have profound consequences, hindering access to appropriate treatment and support. While there is currently no cure for SMA, advancements in treatment options, such as gene therapy and disease-modifying drugs, offer hope for slowing disease progression and improving quality of life. Early diagnosis is critical to maximizing the benefits of these therapies. The U.S. Food and Drug Administration (FDA) approved the first gene therapy for SMA, Zolgensma, in 2019, marking a significant milestone in the treatment of this devastating condition.
Challenges in Diagnosis and Access to Care
Several factors contribute to the diagnostic challenges associated with rare diseases. The rarity of these conditions means that many healthcare professionals lack familiarity with their symptoms, leading to misdiagnosis or delayed recognition. The genetic complexity of many rare diseases can make accurate diagnosis difficult, requiring specialized genetic testing and expertise.
Access to care also presents a significant barrier for individuals with rare diseases, particularly those living in rural or underserved areas. Specialized medical centers and experts are often concentrated in urban areas, requiring patients to travel long distances for treatment. The cost of diagnosis, treatment, and ongoing care can also be substantial, placing a significant financial burden on families.
Raising Awareness and Supporting Families
International Rare Disease Day, observed annually on February 29th (or 28th in non-leap years), aims to raise awareness about rare diseases and advocate for improved access to diagnosis, treatment, and support. Initiated by EURORDIS (European Organisation for Rare Diseases), the day serves as a platform for patients, families, and healthcare professionals to share their experiences and advocate for change.
Organizations like the National Organization for Rare Disorders (NORD) in the United States and EURORDIS play a vital role in supporting individuals and families affected by rare diseases. These organizations provide information, resources, advocacy, and research funding. They also function to connect patients and families with others facing similar challenges, fostering a sense of community and support.
Andréa’s story serves as a powerful reminder of the human impact of rare diseases and the importance of continued research, improved access to care, and increased awareness. Her determination to advocate for her children and navigate the complexities of their condition is an inspiration to others facing similar challenges. The need for early and accurate diagnosis, coupled with ongoing support for families, remains paramount in improving the lives of those affected by these often-overlooked conditions.
As research into rare diseases continues to advance, and new therapies emerge, We see crucial to ensure equitable access to these innovations for all patients, regardless of their location or socioeconomic status. The journey for families like Andréa’s is far from over, but with continued dedication and collaboration, there is hope for a brighter future.
Next Steps: The Brazilian Ministry of Health is currently reviewing policies regarding access to gene therapies for rare diseases. Updates on these policies are expected in the coming months. Readers are encouraged to share their experiences and connect with rare disease support organizations to learn more and advocate for change.